タンパク質チロシンフォスファタゼのアレル特異的阻害剤
Hillary E Hoffman1, Elizabeth R Blair, James E Johndrow
1Department of Chemistry, Amherst College, Amherst, Massachusetts 01002, USA.
Journal of the American Chemical Society
|March 3, 2005
まとめ
研究者は,選択的に抑制されるようにタンパク質チロシンフォスファタゼ (PTPs) を設計しました. この戦略は,細胞シグナル伝達経路の研究のための新しいPTP阻害剤を作成します.
科学分野:
- バイオケミストリー バイオケミストリー
- 分子生物学は分子生物学である.
- 酵素学 酵素学とは
背景:
- タンパク質チロシンフォスファタゼ (PTPs) は,細胞信号伝達経路の重要な調節体です.
- 選択的PTP阻害剤の開発は,保存された活性サイトアーキテクチャのために困難です.
- ターゲットを絞ったPTP抑制は,複雑なリン酸化ネットワークの解剖に不可欠です.
研究 の 目的:
- 標的の選択性を達成するために,PTP/阻害剤インターフェースを設計する.
- サイト指向型ミュータゲネシスを用いて"阻害剤感受性"のPTP突然変異を生成する.
- 改変したPTPを選択的に標的とする新しい阻害剤を特定する.
主な方法:
- PTP1B酵素に対して,サイト指向型変異を生成した.
- 幅広い特異性のPTP阻害剤を化学的に改変した.
- 改変阻害剤は,野生型および変異型PTP1B.に対してスクリーニングされました.
主要な成果:
- Ile219Ala PTP1B変異体が生成され,改変した阻害剤に対する感受性を示した.
- 野生型PTP1Bに対するIle219Ala PTP1Bの選択的阻害を達成しました.
- Ile219Ala変異は,T細胞PTPに対する阻害剤の感受性を授与し,より広範な適用性を示した.
結論:
- PTP/阻害剤のインターフェイスを再設計することは,選択的PTP阻害剤を開発するための実行可能な戦略です.
- 単一の点変異は,様々な阻害剤に敏感なPTP変異を生成することができます.
- このアプローチは,細胞シグナル伝達におけるPTP機能の研究のためのツールを生成するための有望な経路を提供します.
関連する概念動画
01:08Allosteric Regulation
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:52Eukaryotic Transcription Inhibitors
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...